What It Is
CJC-1295 without DAC is the 29-amino-acid GHRH analogue that FDA calls CJC-1295 free base; its acetate salt is a separate bulk drug substance. It lacks the albumin-binding Drug Affinity Complex used in the long-acting DAC active moiety.[1]
Online names such as no DAC and modified GRF (1-29) are used inconsistently. FDA found mismatches among names, structures, identifiers, certificates of analysis, and cited studies, so a product name alone does not establish identity.[1]
Mechanism Is Assumed, Not Demonstrated
CJC-1295 without DAC is intended as a GHRH analogue, but FDA found no studies establishing that CJC-1295 free base or acetate is pharmacologically active.[1] The well-known human findings of multi-day growth-hormone and IGF-1 elevation came from a DAC active moiety, not from the no-DAC forms.[2]
What the Research Shows
FDA found no human study of CJC-1295 free base or acetate without DAC and no human effectiveness study of any form in growth hormone deficiency. A terminated HIV-visceral-obesity trial did not identify which form it intended to study and produced no usable clinical result.[1][3]
Claims about muscle, fat loss, sleep, recovery, anti-aging, dosing frequency, or duration are therefore unsupported extrapolations from a different active moiety or from general GHRH biology.
Safety and Unknowns
FDA found no clinical safety information for CJC-1295 free base or acetate without DAC. The adverse-event record from small DAC studies cannot be assumed to apply, yet it also cannot rule out risks associated with GH/IGF-1 stimulation, impurities, aggregation, or immunogenicity.[1][4]
There is no approved label, validated human formulation, established route, or standard human dose for the no-DAC material.
Regulatory and Sport Status
CJC-1295 free base and acetate are not FDA-approved. FDA proposed not adding them, or any reviewed DAC form, to the 503A Bulks List.[1] Growth hormone-releasing factors are prohibited under the WADA Prohibited List.[5]
The Evidence Boundary
A statement such as CJC-1295 raises IGF-1 for days describes the DAC active moiety studied in healthy adults. Applying it to a no-DAC vial is not supported by direct human evidence. The correct conclusion is not that no-DAC is shorter acting by a known amount, but that its human pharmacology, effectiveness, and safety remain unestablished.[1][2]